{"id":"htig","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory checkpoint receptor expressed on T cells and NK cells. By blocking TIGIT, HTIG prevents its interaction with ligands (CD155 and CD112) on tumor and antigen-presenting cells, thereby relieving immune suppression and promoting T-cell activation and proliferation against cancer cells. This mechanism complements other checkpoint inhibitors like anti-PD-1/PD-L1 therapies.","oneSentence":"HTIG is a humanized anti-TIGIT monoclonal antibody that blocks the TIGIT immune checkpoint to enhance T-cell mediated anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:16.996Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in clinical development)"}]},"trialDetails":[{"nctId":"NCT07149454","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection","status":"ENROLLING_BY_INVITATION","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","startDate":"2025-08-18","conditions":"Tetanus","enrollment":68},{"nctId":"NCT07347938","phase":"","title":"A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury","status":"NOT_YET_RECRUITING","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2026-01-05","conditions":"Tetanus","enrollment":6000},{"nctId":"NCT05625477","phase":"PHASE2","title":"Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2022-04-18","conditions":"Tetanus","enrollment":240},{"nctId":"NCT06939777","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-04","conditions":"Tetanus","enrollment":255},{"nctId":"NCT06635798","phase":"PHASE3","title":"A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2024-09-03","conditions":"Tetanus","enrollment":582},{"nctId":"NCT06360250","phase":"EARLY_PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2024-04-10","conditions":"Clostridium Tetanus","enrollment":190},{"nctId":"NCT06302374","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2023-03-04","conditions":"Tetanus","enrollment":202},{"nctId":"NCT05664750","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2022-12-22","conditions":"Tetanus","enrollment":675}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HTIG","genericName":"HTIG","companyName":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","companyId":"zhuhai-trinomab-pharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"HTIG is a humanized anti-TIGIT monoclonal antibody that blocks the TIGIT immune checkpoint to enhance T-cell mediated anti-tumor immunity. Used for Advanced or metastatic solid tumors (in clinical development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}